Tempus AI Reports Strong Q3 2025 Financial Growth

An announcement from Tempus AI, Inc. Class A ( (TEM) ) is now available.

Tempus AI, Inc. reported significant financial growth for the third quarter of 2025, with revenue increasing by 84.7% year-over-year to $334.2 million and gross profit improving by 98.4%. The company delivered 217,000 clinical tests, with notable growth in oncology and hereditary testing. Despite a net loss of $80 million, Tempus achieved a positive adjusted EBITDA of $1.5 million, marking an important milestone. The company also expanded its operations by acquiring Paige, an AI company specializing in digital pathology, and received FDA clearance for several AI-powered medical devices. Tempus increased its full-year revenue guidance to $1.265 billion, representing approximately 80% growth year-over-year.

The most recent analyst rating on (TEM) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on Tempus AI, Inc. Class A stock, see the TEM Stock Forecast page.

Spark’s Take on TEM Stock

According to Spark, TipRanks’ AI Analyst, TEM is a Neutral.

The overall stock score for Tempus AI, Inc. is driven by strong technical indicators and positive earnings call highlights, including significant revenue growth and strategic deals. However, the score is tempered by poor financial performance, particularly in profitability and cash flow, and a weak valuation due to negative earnings.

To see Spark’s full report on TEM stock, click here.

More about Tempus AI, Inc. Class A

Tempus AI, Inc. is a technology company focused on advancing precision medicine through the application of artificial intelligence in healthcare. It provides AI-enabled precision medicine solutions to physicians, facilitating personalized patient care and the development of optimal therapeutics.

Average Trading Volume: 9,258,130

Technical Sentiment Signal: Buy

Current Market Cap: $15.41B

Find detailed analytics on TEM stock on TipRanks’ Stock Analysis page.